Although FAC3 patients upregulated the expression of PD-L1, we postulated that CRC patients with FAC3 pattern couldn't effectively respond to immunotherapy because the TGF-β pathways and myofibroblasts impeded the penetration of cytotoxic CD8+ T cells into the tumor parenchyma. The gene discussed is TGFB1; the disease is neoplasm.